Over the last two decades, considerable progress has been made in the management of Acute Myocardial Infarction (AMI), both in the acute phase and in monitoring beyond the hospital phase. Nevertheless, the evolution of care practices and their impact on the mid- and long-term prognosis of patients admitted to the intensive care unit for acute myocardial infarction remain relatively little studied exhaustively.
The aim of this study is to assess the profile of AMI patients, their management and follow-up in order to evaluate the relationship between these factors and outcomes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Myocardial infarction (MI) within 48h of symptom onset, characterized by the typical increased or fall of troponin (or CPKMB) associated with at least one of the following elements :
* Symptoms compatible with myocardial ischemia
* Appearance of pathological Q waves
* ST- T changes compatible with myocardial ischemia (ST segment elevation or depression, T-wave inversion)
* Written consent.
* Covered by French medical insurance ("Sécurité Sociale")
Exclusion Criteria:
* Iatrogenic MI defined as MI occurring within 48h of a therapeutic procedure
* AMI diagnosis invalidated in favor of another diagnosis
Primary outcome measure(s)
In-hospital mortality — Through the end of initial hospitalization, an average of 5 days In-hospital mortality
In-hospital outcomes — Through the end of initial hospitalization, an average of 5 days To measure the in-hospital major cardiovascular events : recurrence of AMI, myocardial revascularization, stroke
Lipopretein 1 evolution — 9 months after the end of initial hospitalization To evaluate plasma concentrations of Lpa and its dynamic pattern during hospital index and 3-9 months following hospitalization.
Trial sites (1)
Facility
City
Region
Status
Hôpital Bichat, AP-HP
Paris
France
Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
